

Company registration number: 438429

**Mid West Regional Drugs Task Force
(Company Limited by Guarantee)**

Financial statements

for the financial year ended 31 December 2025

**Mid West Regional Drugs Task Force
(Company Limited by Guarantee)**

Contents

	Page
Directors and other information	1
Directors report	2 - 4
Directors responsibilities statement	5
Independent auditor's report to the members	6 - 8
Income and expenditure account	9
Balance sheet	10
Statement of changes in funds	11
Notes to the financial statements	12 - 20

Mid West Regional Drugs Task Force
Company limited by guarantee

Directors and other information

Directors	Mick Lacey Rachel O' Donoghue (Appointed 15th April 2025) Jennifer Moroney-Ward (Appointed 15th April 2025) James Finn Maurice Quinlivan Maria Finn (Appointed 15th April 2025)
Secretary	Ann Marie Carey
Registered Charity Number	20071875
CHY Number	18637
Company number	438429
Registered office	P.O. Box 486 Corporate House Mungret Street Limerick
Business address	P.O. Box 486 Corporate House Mungret Street Limerick
Auditor	F.D.C. and Associates Ltd F.D.C. House Wellington Road Cork
Bankers	Bank of Ireland 125 O'Connell Street Limerick

**Mid West Regional Drugs Task Force
(Company Limited by Guarantee)**

Directors report

The directors present their annual report and the audited financial statements of the company for the financial year ended 31 December 2025.

Reference and Administrative Details

The company is a not for profit company with a registered office at P.O. Box 486, Corporate House, Limerick. The company's registered number is 438429.

Directors

The names of the persons who at any time during the financial year were directors of the company are:

Mick Lacey
James Finn
Maurice Quinlivan
Maria Finn
Rachel O' Donoghue
Jennifer Moroney-Ward

Principal activities and objectives

The principal activity of the company during the year was to research, develop, implement and monitor a co-ordinated response to drug use at regional level. The directors are satisfied that the company continues to meet it's objectives in this regard.

Achievements and performance

The MWRDTF continued to work in line with the National Drugs Strategy 2017-2025 'Reducing Harm Supporting Recovery'. The MWRDTF also continues to provide funding support to a range of services addressing the impact of substance misuse in the Mid-West region. The Forum also co-ordinates a range of networks and committees that have been set up under the various lead actions in the National Drugs Strategy. In addition the Forum co-ordinates a range of interventions and supports including seminars, training and the dissemination of information to name but a few. Some achievements include:

- Development of a new strategic plan for 2024-2026
- Redesign the forums website and have all drug and alcohol information more accessible to the public.
- Development of a community network and create a support system for new community reps for the forum.
- Continued growth of S.H.E.P. programme into Co. Limerick
- Research and development and the inclusion of peers to capture their experiences.
- Developing a community sharps instead of drug litter, as we continue to reduce the stigma associated with drugs.
- To support the roll out of care and case management across drug and alcohol services in the Mid-West Region.

Financial review

The Company is dependent on state funding. In common with many state funded companies there is the risk of reductions in the levels of funding due to the current downturn in economic activities. The directors are satisfied however that the company will be able to operate despite the cutbacks and that it can operate with the resources provided for the foreseeable future.

At the end of the year the company has assets of €229,139 (2024: €59,978) and liabilities of €70,188, (2024: €79,827). The net assets of the company have increased by €6,468 and the directors are satisfied with the level of retained funds at the year-end.

**Mid West Regional Drugs Task Force
(Limited by Guarantee and not having Share Capital)**

Directors report

Reserves policy

The company's funds are restricted to the activities specified by the funder and are expected to be spent in the short term. The company does not have any investments and as a not for profit company does not envisage a situation whereby the company has more funds that is required to fund ongoing expenditure.

Structure, Governance and Management

The company is a not for profit company limited by guarantee. The company does not have a share capital and consequently the liability of members is limited, subject to an undertaking by each member to contribute to the net assets or liabilities of the company on winding up such amounts as may be required not exceeding one Euro (€1) .

Management Structure. The company was established under a Constitution which established the objects and powers of the company and is governed under its Constitution and managed by a Board of Directors. The Board of Directors include some who live and or work in the local Community. The directors act in a voluntary capacity and do not receive any remuneration. The Board consists of a Chairperson, Vice Chairperson, Secretary and Committee. The company is managed by a full-time administrator. The management team have worked very hard over the past years building and developing on our aims and objectives. The management team meet on a regular basis to carry out and monitor progress on ongoing projects and services.

The company currently has four directors who meet on a quarterly basis and are responsible for the strategic direction of the company. At these meetings the board of directors are provided with the key performance and risk indicators. The administrator is responsible for ensuring that the company meets its long and short term aims and the day to day operations run smoothly.

The board held four meetings during 2025 with an average attendance of 80%.

Likely future developments

The directors are not expecting to make significant changes in the nature of the business in the near future.

Events after the end of the reporting period

There have been no significant events affecting the company since the year end.

Accounting records

The measures taken by the directors to secure compliance with the requirements of sections 281 to 285 of the Irish Generally Accepted Accounting Practice in Ireland with regard to the keeping of accounting records are the implementation of necessary policies and procedures for recording transactions, the employment of competent accounting personnel with appropriate expertise and the provision of adequate resources to the financial function. The accounting records of the company are located at P.O. Box 486, Corporate House, Mungret Street, Limerick.

Relevant audit information

In the case of each of the persons who are directors at the time this report is approved in accordance with section 332 of Irish Generally Accepted Accounting Practice in Ireland:

- so far as each director is aware, there is no relevant audit information of which the company's statutory auditors are unaware, and
- each director has taken all the steps that he or she ought to have taken as a director in order to make himself or herself aware of any relevant audit information and to establish that the company's statutory auditors are aware of that information.


**Mid West Regional Drugs Task Force
(Limited by Guarantee and not having Share Capital)**


Directors report

Auditors

The auditors, F.D.C. and Associates Ltd, have expressed their willingness to continue in office in accordance with the provisions of Section 383(2) of the Companies Act 2014.

Approved by the board of directors on 30 April 2026 and signed on its behalf by:


Mick Lacey
Director


James Finn
Director

**Mid West Regional Drugs Task Force
(Limited by Guarantee and not having Share Capital)**

Directors responsibilities statement

The directors are responsible for preparing the directors report and the financial statements in accordance with applicable Irish law and regulations.


Irish company law requires the directors to prepare financial statements for each financial year, giving a true and fair view of the state of affairs of the Company. Under the law, the directors have elected to prepare the financial statements in accordance with the Irish Generally Accepted Accounting Practice in Ireland, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the Republic of Ireland' and Irish law. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the surplus or deficit of the company for the financial year and otherwise comply with the Irish Generally Accepted Accounting Practice in Ireland.


In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgments and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and surplus or deficit of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and directors report comply with the Irish Generally Accepted Accounting Practice in Ireland and enable the financial statements to be audited. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

This statement was approved by the board on the 30 April 2026 and signed on it's behalf by:


Mick Lacey
Director


James Finn
Director

**Mid West Regional Drugs Task Force
(Limited by Guarantee and not having Share Capital)**

Report on the audit of the financial statements

Opinion

We have audited the financial statements of Mid West Regional Drugs Task Force (the 'company') for the financial year ended 31 December 2025 which comprise the Income & Expenditure Account, balance sheet, statement of changes in equity and notes to the financial statements, including a summary of significant accounting policies set out in note 3. The financial reporting framework that has been applied in their preparation is Irish law and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland.

In our opinion, the financial statements:

- give a true and fair view of the assets, liabilities and financial position of the company as at 31 December 2025 and of its loss for the financial year then ended;
- have been properly prepared in accordance with FRS United Kingdom Generally Accepted Accounting Practice and
- have been prepared in accordance with the requirements of the Irish Generally Accepted Accounting Practice in Ireland.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are further described in the auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in Ireland, including the Ethical Standard issued by the Irish Auditing and Accounting Supervisory Authority (IAASA), and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other Information

The directors are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information. We do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

**Mid West Regional Drugs Task Force
(Company Limited by Guarantee)**

Opinions on other matters prescribed by the Irish Generally Accepted Accounting Practice in Ireland

Based solely on the work undertaken in the course of the audit, we report that:

- in our opinion, the information given in the report is consistent with the financial statements; and
- in our opinion, the report has been prepared in accordance with applicable legal requirements.

We have obtained all the information and explanations which we consider necessary for the purposes of our audit.

In our opinion the accounting records of the company were sufficient to permit the financial statements to be readily and properly audited, and financial statements are in agreement with the accounting records.

Matters on which we are required to report by exception

Based on the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the report.

The Irish Generally Accepted Accounting Practice in Ireland requires us to report to you if, in our opinion, the disclosures of directors' remuneration and transactions required by sections 305 to 312 of the Act are not made. We have nothing to report in this regard.

Respective responsibilities

Responsibilities of directors for the financial statements

As explained more fully in the responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the management either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

**Mid West Regional Drugs Task Force
(Company Limited by Guarantee)**

As part of an audit in accordance with ISAs (Ireland), we exercise professional judgment and maintain professional scepticism throughout the audit. also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

The purpose of our audit work and to whom we owe our responsibilities

Our report is made solely to the company's members, as a body, in accordance with section 391 of the Irish Generally Accepted Accounting Practice in Ireland Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members, as a body, for our audit work, for this report, or for the opinions we have formed.

Enda Ryan (Senior Statutory Auditor)

For and on behalf of
F.D.C. and Associates Ltd
Chartered Certified Accountants & Statutory Auditors
F.D.C. House
Wellington Road
Cork

**Mid West Regional Drugs Task Force
(Limited by Guarantee and not having Share Capital)**

**Income and expenditure account
Financial year ended 31 December 2025**

	Note	2025 €	2024 €
Income	4		
Donations and Grants		499,005	405,898
		<u>499,005</u>	<u>405,898</u>
Expenditure			
Direct charitable expenditure	7	501,123	409,404
Governance Costs		4,350	4,350
		<u>505,473</u>	<u>413,754</u>
Deficit for the financial year		<u>(6,468)</u>	<u>(7,856)</u>

The company has no other recognised items of income and expenses other than the results for the financial year as set out above.

The notes on pages 12 to 20 form part of these financial statements.


Mid West Regional Drugs Task Force
(Limited by Guarantee and not having Share Capital)


Balance sheet
As at 31 December 2025

	Note	2025 €	€	2024 €	€
Fixed assets					
Tangible assets	9	1,029		2,176	
			1,029		2,176
Current assets					
Debtors	10	3,011		14,560	
Cash at bank and in hand		225,099		43,242	
		228,110		57,802	
Creditors: amounts falling due within one year	11	(200,277)		(23,507)	
Net current assets			27,833		34,295
Total assets less current liabilities			28,862		36,471
Creditors: amounts falling due after more than one year			-		(1,142)
Net assets			28,862		35,329
Funds:					
Restricted funds			28,862		35,329
Total funds			28,862		35,329

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

These financial statements were approved by the board of directors on 30 April 2026 and signed on behalf of the board by:


Mick Lacey
Director


James Finn
Director

The notes on pages 12 to 20 form part of these financial statements.

**Mid West Regional Drugs Task Force
(Company Limited by Guarantee)**

**Statement of changes in funds
Financial year ended 31 December 2025**

	Restricted Funds	Total
	€	€
At 1 January 2024	43,185	43,185
Deficit for the financial year	(7,856)	(7,856)
At 31 December 2024 and 1 January 2025	35,330	35,330
Deficit for the financial year	(6,468)	(6,468)
At 31 December 2025	<u>28,862</u>	<u>28,862</u>

**Mid West Regional Drugs Task Force
(Company Limited by Guarantee)**

**Notes to the financial statements
Financial year ended 31 December 2025**

1. General information

The company is a private company limited by guarantee, registered in Ireland. The address of the registered office is P.O. Box 486, Corporate House, Mungret Street, Limerick and its registered number is 438429. The principal activity of the company is to research, develop, implement and monitor a co-ordinated response to drug use at regional level.

2. Statement of compliance

These financial statements have been prepared in compliance with FRS 102 Section 1A, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

3. Accounting policies and measurement bases

Basis of preparation

The financial statements have been prepared on the going concern basis and under the historical cost convention and comply with the financial reporting standards of the Financial Reporting Council including FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102"), as modified by Section 1A of FRS 102 and the Companies Act 2014.

The financial statements are prepared in Euro, which is the functional currency of the entity.

Change in formats

The directors have availed of the provisions of Section 291(5) of the Companies Act 2014 to use a format for the financial statements that better describes the activities of a company not trading for a profit. The main change being the replacement of the title "profit and loss" with the title "Income and Expenditure" and consequential changes in descriptions of certain items to be consistent with the descriptions appropriate to the not for profit sector.

Judgements and key sources of estimation uncertainty

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses. Judgements and estimates are continually evaluated and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Income

The company is funded mainly by grants from state agencies. These grants are treated as income in the period to which they relate. All other income is recognised in the period in which it is received.

**Mid West Regional Drugs Task Force
(Company Limited by Guarantee)**

**Notes to the financial statements (continued)
Financial year ended 31 December 2025**

Expenditure

Expenditure is recognised on an accrual basis as a liability is incurred.

Costs of generating funds comprise the costs associated with the administration of the HSE funds and other grants and sources of income.

Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

Governance costs include those costs associated with meeting the constitutional and statutory requirements of the charity and include the audit fees and costs linked to the strategic management of the charity.

All costs are allocated between the expenditure categories of the Income & Expenditure Account on a basis designed to reflect the use of the resource.

Taxation

No charge to current or deferred taxation arises as the charity has been granted charitable status under Sections 207 and 208 of the Taxes Consolidation Act 1997, Charity No CHY 18637. The charity is eligible under the "Scheme of Tax Relief for Donations to Eligible Charities and Approved Bodies under Section 848A Taxes Consolidation Act, 1997" therefore income tax refunds arising from sponsorships exceeding €250 per annum are included in unrestricted funds. Irrecoverable value added tax is expended as incurred.

Foreign currencies

Foreign currency transactions are initially recorded in the functional currency, by applying the spot exchange rate as at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the exchange rate ruling at the reporting date, with any gains or losses being taken to profit or loss.

Tangible assets

Tangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated depreciation and impairment losses.

Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in capital and reserves, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in capital and reserves in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in capital and reserves in respect of that asset, the excess shall be recognised in profit or loss.

**Mid West Regional Drugs Task Force
(Company Limited by Guarantee)**

**Notes to the financial statements (continued)
Financial year ended 31 December 2025**

Depreciation

Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

Office equipment	- 25%	straight line
Computer equipment	- 25%	straight line

If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates.

Impairment

A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.

When it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets.

Government grants

Government grants are recognised at the fair value of the asset received or receivable. Grants are not recognised until there is reasonable assurance that the company will comply with the conditions attaching to them and the grants will be received.

Government grants are recognised using the accrual model.

Under the accrual model, government grants relating to revenue are recognised on a systematic basis over the periods in which the company recognises the related costs for which the grant is intended to compensate. Grants that are receivable as compensation for expenses or losses already incurred or for the purpose of giving immediate financial support to the entity with no future related costs are recognised in income in the period in which it becomes receivable.

Grants relating to assets are recognised in income on a systematic basis over the expected useful life of the asset. Where part of a grant relating to an asset is deferred, it is recognised as deferred income and not deducted from the carrying amount of the asset.

**Mid West Regional Drugs Task Force
(Company Limited by Guarantee)**

**Notes to the financial statements (continued)
Financial year ended 31 December 2025**

Provisions

Provisions are recognised when the entity has an obligation at the reporting date as a result of a past event; it is probable that the entity will be required to transfer economic benefits in settlement and the amount of the obligation can be estimated reliably. Provisions are recognised as a liability in the balance sheet and the amount of the provision as an expense.

Provisions are initially measured at the best estimate of the amount required to settle the obligation at the reporting date and subsequently reviewed at each reporting date and adjusted to reflect the current best estimate of the amount that would be required to settle the obligation. Any adjustments to the amounts previously recognised are recognised in profit or loss unless the provision was originally recognised as part of the cost of an asset. When a provision is measured at the present value of the amount expected to be required to settle the obligation, the unwinding of the discount is recognised in finance costs in profit or loss in the period it arises.

Cash and cash equivalents

Cash and cash equivalents include cash on hand, demand deposits and other short- term highly liquid investments with original maturities of three months or less. Bank overdrafts are shown within borrowings in current liabilities on the statement of financial position.

Fund accounting

The following funds are operated by the company:

Restricted Funds

Restricted Funds represent grants, donations and sponsorships received which can only be used for particular purposes specified by the donors or sponsorship programmes binding on the directors/trustees. Such purposes are within the overall aims of the company.

Unrestricted Funds

Unrestricted Funds represent amounts which are expendable at the discretion of the Directors/Trustees in furtherance of the objectives of the charity and which have not been designated for other purposes. Such funds may be held in order to finance working capital or capital expenditure.

Designated Funds

Designated funds are unrestricted funds earmarked by the Directors/Trustees for particular purposes. The aim and use of each designated fund is set out in the notes to the financial statements. The designations have an administrative purpose only and do not legally restrict the Board's discretion in applying the funds.

Contingencies

Contingent liabilities, arising as a result of past events, are not recognised when (i) it is not probable that there will be an outflow of resources or that the amount cannot be reliably measured at the reporting date or (ii) when the existence will be confirmed by the occurrence or non-occurrence of uncertain future events not wholly within the company's control. Contingent liabilities are disclosed in the financial statements unless the probability of an outflow of resources is remote.

Contingent assets are not recognised. Contingent assets are disclosed in the financial statements when an inflow of economic benefits is probable.

**Mid West Regional Drugs Task Force
(Company Limited by Guarantee)**

**Notes to the financial statements (continued)
Financial year ended 31 December 2025**

4. Critical Accounting Judgements and Estimates

The preparation of these financial statements requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses

Judgements and estimates are continually evaluated and are based on historical experiences and other factors, including expectations of future events that are believed to be reasonable under the circumstances

The company makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.

Establishing useful economic lives for depreciation purposes of property, plant and equipment

Long-lived assets, consisting primarily of property, plant and equipment, comprise a significant portion of the total assets. The annual depreciation charge depends primarily on the estimated useful economic lives of each type of asset and estimates of residual values. The directors regularly review these asset useful economic lives and change them as necessary to reflect current thinking on remaining lives in light of prospective economic utilisation and physical condition of the assets concerned. Changes in asset useful lives can have a significant impact on depreciation and amortisation charges for the period. Detail of the useful economic lives is included in the accounting policies.

5. Limited by guarantee

Mid West Regional Drugs Task Force is a company limited by guarantee having no share capital and consequently the liability of members is limited, subject to an undertaking by each member to contribute to the net assets or liabilities of the company on winding up such amounts as may be required not exceeding one Euro

6. Operating deficit

Operating deficit is stated after charging/(crediting):

	2025	2024
	€	€
Depreciation of tangible assets	1,148	1,761
(Gain)/loss on disposal of tangible assets	-	260
Fees payable for the audit of the financial statements	4,350	4,350
	<u> </u>	<u> </u>

**Mid West Regional Drugs Task Force
(Company Limited by Guarantee)**

**Notes to the financial statements (continued)
Financial year ended 31 December 2025**

7. Staff costs

The average number of persons employed by the company during the financial year was 5 (2024: 4).

The aggregate payroll costs incurred during the financial year were:

	2025	2024
	€	€
Wages and salaries	246,144	177,092
Social insurance costs	27,524	19,127
	<u>273,668</u>	<u>196,219</u>

8. Directors remuneration

No members of the management committee received any remuneration during the year (2024:Nil). No trustee or other person related to the company had any personal interest in any contract or transaction entered into by the company during the year (2024:Nil).

Key management includes the Board of Directors (executive and non-executive), all members of the Company Management and the Company Secretary. The compensation paid or payable to key management for employee services is shown below:

<u>Employee Benefits</u>	Number of
€60,000 - €70,000	1
€70,000 or greater	Nil
Total Employer Pension Contributions	Nil

**Mid West Regional Drugs Task Force
(Company Limited by Guarantee)**

**Notes to the financial statements (continued)
Financial year ended 31 December 2025**

9. Tangible assets

	Computer equipment €	Office equipment €	Total €
Cost			
At 1 January 2025	9,169	3,076	12,245
Disposals	(1,351)	-	(1,351)
At 31 December 2025	<u>7,818</u>	<u>3,076</u>	<u>10,894</u>
Depreciation			
At 1 January 2025	6,992	3,076	10,068
Charge for the financial year	1,148	-	1,148
Disposals	(1,351)	-	(1,351)
At 31 December 2025	<u>6,789</u>	<u>3,076</u>	<u>9,865</u>
Carrying amount			
At 31 December 2025	<u>1,029</u>	<u>-</u>	<u>1,029</u>
At 31 December 2024	<u>2,177</u>	<u>-</u>	<u>2,177</u>

10. Debtors

	2025 €	2024 €
Prepayments - expenses	3,011	-
Accrued income	-	14,560
	<u>3,011</u>	<u>14,560</u>

The fair values of trade and other receivables approximate to their carrying amounts.

11. Creditors: amounts falling due within one year

	2025 €	2024 €
PAYE and social welfare	28,156	15,462
Accruals	4,252	4,545
Deferred income	167,869	3,500
	<u>200,277</u>	<u>23,507</u>

Trade and other creditors are payable at various dates in the next twelve months in accordance with the usual suppliers terms.

Tax and social securities are repayable at various dates over the coming months in line with tax authority guidelines.

**Mid West Regional Drugs Task Force
(Company Limited by Guarantee)**

**Notes to the financial statements (continued)
Financial year ended 31 December 2025**

12 State Grants

(a)	Grantor	Grant Name	Grant Purpose	Grant Award	Grant Receipts	Op Grant Accrued	Op Grant Deferred	To Capital Grants	CI Grant Deferred	CI Grant Accrued	Grant Income	Type	Expenditure in the per
				€	€	€	€	€	€	€	€		
	H.S.E.	Mid West and City	Operational	206,833	206,833						206,833	R	206
	H.S.E.	WRC pay award	Operational	24,165	39,908	(14,560)					25,348	R	25
	H.S.E.	Strand 1	Operational	10,000	10,000						10,000	R	10
	H.S.E.	Research	Admin	12,000	12,000						12,000	R	12
	H.S.E.	ELS	Admin	10,000	10,000				(2,500)		7,500	R	7
	H.S.E.	LLADAT	Project Costs	18,865	18,865				(5,000)		13,865	R	13
	H.S.E.	Recovery grant	Operational	100,000	215,000				(155,064)		59,936	R	59
	H.S.E.	Small Grants	Project Costs	38,800	38,800						38,800	R	38
	H.S.E.	Treatment & Rehab	Project Costs	29,365	29,365						29,365	R	29
	H.S.E.	Sustain CommunityBased Drugs Service	Project Costs	15,000	15,000						15,000	R	15
	LCETB -Dept of Children & Youth Affairs	Education, Prevention & Training	Project Costs	80,575	80,575				(5,305)		75,270	R	80
				545,603	676,346	14,560			(167,869)		493,917		499

R = Restricted

(b) Tax Clearance

The company is compliant with relevant circulars, including Circular 44/2006 "Tax Clearance Procedures Grants, Subsidies and Similar Type Payments".

This note is in adherence with the requirements set out in Circular 13/2014 which supercedes Circular 17/2010.

**Mid West Regional Drugs Task Force
(Company Limited by Guarantee)**

**Notes to the financial statements (continued)
Financial year ended 31 December 2025**

13. Events after the end of the reporting period

Funding is in place for 2026 and the directors are confident that the services provided by the company will be considered essential and that funding will be maintained for the foreseeable future.

14. Controlling party

The company is controlled by its board of directors.

15. Ethical standards

As a small entity under the provisions of the APB in relation to Ethical Standards we engage our auditor to provide CRO filing and accounts preparation services.

16. Approval of financial statements

The board of directors approved these financial statements for issue on 30 April 2026.

**Mid West Regional Drugs Task Force
(Company Limited by Guarantee)**

The following pages do not form part of the statutory accounts.

**Mid West Regional Drugs Task Force
(Company Limited by Guarantee)**

**Detailed income & expenditure account
Financial year ended 31 December 2025**

	2025 €	2024 €
Income		
H.S.E.	418,430	325,323
Limerick and Clare Education & Training Board	80,575	80,575
	<u>499,005</u>	<u>405,898</u>
 Administrative expenses		
Wages and salaries	246,144	177,092
Employer's PRSI contributions	27,524	19,127
Supervision	800	780
Rent Payable	6,000	6,000
Repairs and maintenance	242	-
IT costs	9,344	9,357
Office Supplies & Services	5,596	5,717
Promotion & Advertising	360	50
Training	1,940	995
Telephone	6,675	6,357
Meeting Expenses	10,391	7,708
Parking	3,900	1,755
Reimbursement to funding agency	6,197	-
Project Costs	159,935	145,208
Travelling and subsistence	4,707	12,288
Legal and professional	3,756	4,717
Consultancy fees	-	5,606
Auditors remuneration	4,350	4,350
Bank charges	231	228
General expenses	7,375	6,159
Depreciation of tangible assets	1,148	1,761
Gain/loss on disposal of tangible assets	-	260
Capital Grant Released	(1,142)	(1,761)
	<u>505,473</u>	<u>413,754</u>
 Deficit for year	 <u><u>(6,468)</u></u>	 <u><u>(7,856)</u></u>